The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: A meta-analysis

Current Neuropharmacology

Volumn 13, Issue 5, 2015, Pages 681-691

  Thomas, Jennifer E ^a   Caballero, Joshua ^a   Harrington, Catherine A ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH FLORIDA   (United States)

Author keywords

Akathisia; Aripiprazole; Asenapine; Lurasidone

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; LURASIDONE; OLANZAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; ZIPRASIDONE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AGITATION; AKATHISIA; ANXIETY; ARTICLE; ASSESSMENT OF HUMANS; BARNES AKATHISIA SCALE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM RATING SCALE; HUMAN; NERVOUSNESS; OUTCOME ASSESSMENT; PARKINSONISM; RESTLESSNESS; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; SUICIDAL IDEATION; SUICIDE; SYSTEMATIC REVIEW; AKATHISIA, DRUG-INDUCED; ANIMAL; INCIDENCE; META ANALYSIS;

AKATHISIA, DRUG-INDUCED; ANIMALS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; INCIDENCE; LURASIDONE HYDROCHLORIDE; SCHIZOPHRENIA;

EID: 84946741626     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159x13666150115220221     Document Type: Article

References (55)

1. [1] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association, 2013.
2. [2] Rathbone, J.; Soares-Weiser, K. Anticholinergics for neurolepticinduced acute akathisia. Cochrane Database Syst. Rev., 2006, CD003727. http://dx.doi.org/10.1002/14651858.cd003727.pub3
3. [3] Iqbal, N.; Lambert, T.; Masand, P. Akathisia: problem of history or concern of today. CNS Spectr., 2007, 12, 1-16.
4. [4] Sachdev, P. The development of the concept of akathisia: a historical overview. Schizophr. Res., 1995, 16, 33-45. http://dx.doi.org/10.1016/0920-9964(94)00058-G
5. [5] Hirose, S. The causes of underdiagnosing akathisia. Schizophr. Bull., 2003, 29, 547-558. http://dx.doi.org/10.1093/oxfordjournals.schbul.a007027
6. [6] Wada, M.; Ito, H.; Wada, M.; Wada, T.; Tada, Y.; Ishida, M.; Mizuno, K.; Shioi, A.; Narabayashi, M.; Iwamitsu, Y.; Onishi, H. Drug-induced akathisia as a cause of distress in spouse caregivers of cancer patients. Palliat. Support. Care, 2011, 9, 209-212. http://dx.doi.org/10.1017/S1478951511000071
7. [7] Van Putten, T. Why do schizophrenic patients refuse to take their drugs? Arch. Gen. Psychiatry, 1974, 31, 67-72. http://dx.doi.org/10.1001/archpsyc.1974.01760130049008
8. [8] Kane, J.M.; Fleischhacker, W.W.; Hansen, L.; Perlis, R.; Pikalov, A.; Assunção-Talbott, S. Akathisia: an updated review focusing on second-generation antipsychotics. J. Clin. Psychiatry, 2009, 70, 627-643. http://dx.doi.org/10.4088/JCP.08r04210
9. [9] Seemüller, F.; Schennach, R.; Mayr, A.; Musil, R.; Jäger, M.; Maier, W.; Klingenberg, S.; Heuser, I.; Klosterkötter, J.; Gastpar, M.; Schmitt, A.; Schlösser, R.; Schneider, F.; Ohmann, C.; Lewitzka, U.; Gaebel, W.; Möller, H.J.; Riedel, M.; German Study Group on First-Episode Schizophrenia. Akathisia and suicidal ideation in first-episode schizophrenia. J. Clin. Psychopharmacol., 2012, 32, 694-698. http://dx.doi.org/10.1097/JCP.0b013e3182677958
10. [10] Jadad, A.R.; Moore, R.A.; Carroll, D.; Jenkinson, C.; Reynolds, D.J.; Gavaghan, D.J.; McQuay, H.J. Assessing the quality of reports of randomized clinical trials : is blinding necessary? Control. Clin. Trials, 1996, 17, 1-12.
11. [11] Review Manager (RevMan) [Computer Program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
12. [12] Kane, J.M.; Carson, W.H.; Saha, A.R.; McQuade, R.D.; Ingenito, G.G.; Zimbroff, D.L.; Ali, M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry, 2002, 63, 763-771. http://dx.doi.org/10.4088/JCP.v63n0903
13. [13] Pigott, T.A.; Carson, W.H.; Saha, A.R.; Torbeyns, A.F.; Stock, E.G.; Ingenito, G.G. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry, 2003, 64, 1048-1056. http://dx.doi.org/10.4088/JCP.v64n0910
14. [14] Chan, H.Y.; Lin, W.W.; Lin, S.K.; Hwang, T.J.; Su, T.P.T.; Chiang, S.C.; Hwu, H.G. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J. Clin. Psychiatry, 2007, 68, 29-36. http://dx.doi.org/10.4088/JCP.v68n0104
15. [15] Potkin, S.G.; Saha, A.R.; Kujawa, M.J.; Carson, W.H.; Ali, M.; Stock, E.; Stringfellow, J.; Ingenito, G.; Marder, S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry, 2003, 60, 681-690. http://dx.doi.org/10.1001/archpsyc.60.7.681
16. [16] McEvoy, J.P.; Daniel, D.G.; Carson, W.H.; McQuade, R.D.; Marcus, R.N. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J. Psychiatr. Res., 2007, 41, 895-905. http://dx.doi.org/10.1016/j.jpsychires.2007.05.002
17. [17] Zimbroff, D.; Warrington, L.; Loebel, A.; Yang, R.; Siu, C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int. Clin. Psychopharmacol., 2007, 22, 363-370. http://dx.doi.org/10.1097/YIC.0b013e32816f7779
18. [18] Fleischhacker, W.W.; McQuade, R.D.; Marcus, R.N.; Archibald, D.; Swanink, R.; Carson, W.H. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol. Psychiatry, 2009, 65, 510-517. http://dx.doi.org/10.1016/j.biopsych.2008.07.033
19. [19] Kane, J.M.; Osuntokun, O.; Kryzhanovskaya, L.A; Xu, W.; Stauffer, V.L.; Watson, S.B.; Breier, A. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J. Clin. Psychiatry, 2009, 70, 572-581. http://dx.doi.org/10.4088/JCP.08m04421
20. [20] McQuade, R.D.; Stock, E.; Marcus, R.; Jody, D.; Gharbia, N.A; Vanveggel, S.; Archibald, D.; Carson, W.H. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry, 2004, 65 Suppl 1, 47-56.
21. [21] Newcomer, J.W.; Campos, J.A.; Marcus, R.N.; Breder, C.; Berman, R.M.; Kerselaers, W.; L’Italien, G.J.; Nys, M.; Carson, W.H.; McQuade, R.D. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J. Clin. Psychiatry, 2008, 69, 1046-1056. http://dx.doi.org/10.4088/JCP.v69n0702
22. [22] Jindal, K.C.; Singh, G.P.; Munjal, V. Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India. Int. J. Psychiatry Clin. Pract., 2013, 17, 21-29. http://dx.doi.org/10.3109/13651501.2011.653376
23. [23] Kane, J.M.; Mackle, M.; Snow-Adami, L.; Zhao, J.; Szegedi, A.; Panagides, J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J. Clin. Psychiatry, 2011, 72, 349-355. http://dx.doi.org/10.4088/JCP.10m06306
24. [24] Kane, J.M.; Cohen, M.; Zhao, J.; Alphs, L.; Panagides, J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J. Clin. Psychopharmacol., 2010, 30, 106-115. http://dx.doi.org/10.1097/JCP.0b013e3181d35d6b
25. [25] Buchanan, R.W.; Panagides, J.; Zhao, J.; Phiri, P.; den Hollander, W.; Ha, X.; Kouassi, A.; Alphs, L.; Schooler, N.; Szegedi, A.; Cazorla, P.; Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J. Clin. Psychopharmacol., 2012, 32, 36-45. http://dx.doi.org/10.1097/JCP.0b013e31823f880a
26. [26] Schoemaker, J.; Naber, D.; Vrijland, P.; Panagides, J.; Emsley, R. Long-term assessment of asenapine vs . olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry, 2010, 43, 138-146. http://dx.doi.org/10.1055/s-0030-1248313
27. [27] Potkin, S.G.; Cohen, M.; Panagides, J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidonecontrolled trial. J. Clin. Psychiatry, 2007, 68, 1492-1500. http://dx.doi.org/10.4088/JCP.v68n1004
28. [28] Ogasa, M.; Kimura, T.; Nakamura, M.; Guarino, J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013, 225, 519-530. http://dx.doi.org/10.1007/s00213-012-2838-2
29. [29] Loebel, A.; Cucchiaro, J.; Sarma, K.; Xu, L.; Hsu, C.; Kalali, A. H.; Pikalov, A.; Potkin, S. G. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr. Res., 2013, 145, 101-109. http://dx.doi.org/10.1016/j.schres.2013.01.009
30. [30] Meltzer, H.; Cucchiaro, J.; Silva, R.; Ogasa, M.; Phillips, D.; Xu, J.; Kalali, A.; Schweizer, E.; Pikalov, A.; Loebel, A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placeboand olanzapine-controlled study. Am. J. Psychiatry, 2011, 168, 957-967. http://dx.doi.org/10.1176/appi.ajp.2011.10060907
31. [31] Nasrallah, H.A.; Silva, R.; Phillips, D.; Cucchiaro, J.; Hsu, J.; Xu, J.; Loebel, A. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebocontrolled study. J. Psychiatr. Res., 2013, 47, 670-677. http://dx.doi.org/10.1016/j.jpsychires.2013.01.020
32. [32] Nakamura, M.; Ogasa, M.; Guarino, J.; Phillips, D.; Severs, J.; Cucchiaro, J.; Loebel, A. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry, 2009, 70, 829-836. http://dx.doi.org/10.4088/JCP.08m04905
33. [33] Potkin, S.G.; Ogasa, M.; Cucchiaro, J.; Loebel, A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr. Res., 2011, 132, 101-107. http://dx.doi.org/10.1016/j.schres.2011.04.008
34. [34] Citrome, L.; Cucchiaro, J.; Sarma, K.; Phillips, D.; Silva, R.; Tsuchiya, S.; Loebel, A. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, activecontrolled study. Int. Clin. Psychopharmacol., 2012, 27, 165-176. http://dx.doi.org/10.1097/YIC.0b013e32835281ef
35. [35] Sunovion. A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2013 Jul 1]. Available from: http://clinicaltrials.gov/show.
36. [36] Avital, A.; Gross-Isseroff, R.; Stryjer, R.; Hermesh, H.; Weizman, A.; Shiloh, R. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. Eur. Neuropsychopharmacol., 2009, 19, 476-482. http://dx.doi.org/10.1016/j.euroneuro.2009.02.006
37. [37] Zhang, J.P.; Gallego, J.A.; Robinson, D.G.; Malhotra, A.K.; Kane, J.M.; Correll, C.U. Efficacy and safety of individual secondgeneration vs first-generation antipsychotics in first episode psychosis: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol., 2013, 16, 1205-1218. http://dx.doi.org/10.1017/S1461145712001277
38. [38] Poyurovsky, M.; Shardorodsky, M.; Fuchs, C.; Schneidman, M.; Weizman, A. Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. double-blind, placebo-controlled study. Br. J. Psychiatry, 1999, 174, 238-242. http://dx.doi.org/10.1192/bjp.174.3.238
39. [39] Abilify (aripiprazole) [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Co; August 2013.
40. [40] Hirose, T.; Uwahodo, Y.; Yamada, S.; Miwa, T.; Kikuchi, T.; Kitagawa, H.; Burris, K.D.; Altar, C.A.; Nabeshima, T. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J. Psychopharmacol., 2004, 18, 375-383. http://dx.doi.org/10.1177/026988110401800308
41. [41] Shapiro, D.A.; Renock, S.; Arrington, E.; Chiodo, L.A.; Liu, L.X.; Sibley, D.R.; Roth, B. L.; Mailman, R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 2003, 28, 1400-1411. http://dx.doi.org/10.1038/sj.npp.1300203
42. [42] Fleischhacker, W. Aripiprazole. Expert Opin Pharmacother 2005, 6, 2091-2101. http://dx.doi.org/10.1517/14656566.6.12.2091
43. [43] Burris, K.D.; Molski, T.F.; Xu, C.; Ryan, E.; Tottori, K.; Kikuchi, T.; Yocca, F.D.; Molinoff, P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther., 2002, 302, 381-389. http://dx.doi.org/10.1124/jpet.102.033175
44. [44] Inoue, T.; Domae, M.; Yamada, K.; Furukawa, T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther., 1996, 277, 137-143.
45. [45] Saphris (asenapine) [package insert]. Whitehouse Station, NJ: Merck & Co Inc; March 2013.
46. [46] Stoner, S.C.; Pace, H.A. Asenapine: a clinical review of a secondgeneration antipsychotic. Clin. Ther., 2012, 34, 1023-1040. http://dx.doi.org/10.1016/j.clinthera.2012.03.002
47. [47] Shahid, M.; Walker, G.B.; Zorn, S.H.; Wong, E. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol., 2009, 23, 65-73. http://dx.doi.org/10.1177/0269881107082944
48. [48] Tarazi, F.; Moran-Gates, T.; Wong, E.; Henry, B.; Shahid, M. Differential regional and dose-related effects of asenpaine on dopamine receptor subtypes. Psychopharmacology (Berl)., 2008, 198, 103-111. http://dx.doi.org/10.1007/s00213-008-1098-7
49. [49] Marin, C.; Parashos, S.; Kapitzoglou-Logothetis, V.; Peppe, A.; Chase, T. D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol. Biochem. Behav., 1993, 45, 195-200. http://dx.doi.org/10.1016/0091-3057(93)90104-2
50. [50] Zyprexa (olanzapine) [package insert]. Indianapolis, IN: Eli Lilly and Company; July 2013.
51. [51] Latuda (lurasidone hydrochloride) [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc; November 2010.
52. [52] Meyer, J.M.; Loebel, A.D.; Schweizer, E. Lurasidone: a new drug in development for schizophrenia. Expert Opin. Investig. Drugs, 2009, 18, 1715-1726. http://dx.doi.org/10.1517/13543780903286388
53. [53] Ishibashi, T.; Horisawa, T.; Tokuda, K.; Ishiyama, T.; Ogasa, M.; Tagashira, R.; Matsumoto, K.; Nishikawa, H.; Ueda, Y.; Toma, S.; Oki, H.; Tanno, N.; Saji, I.; Ito, A.; Ohno, Y.; Nakamura, M. Pharmacological profile of lurasidone , a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther., 2010, 334, 171-181. http://dx.doi.org/10.1124/jpet.110.167346
54. [54] Seroquel (quetiapine) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2013.
55. [55] Gao, K.; Kemp, D.; Ganocy, S.; Gajwani, P.; Xia, G.; Calabrese, J. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J. Clin. Psychopharmacol., 2012, 28, 203-209. http://dx.doi.org/10.1097/JCP.0b013e318166c4d5